Acetyl-ARNTL (K538) Antibody

What is ARNTL/BMAL1 and what function does acetylation at K538 serve?

ARNTL (also known as BMAL1) is a basic helix-loop-helix protein that forms a heterodimer with CLOCK, binding to E-box enhancer elements upstream of Period (PER1, PER2, PER3) and Cryptochrome (CRY1, CRY2) genes to activate their transcription. These genes' products later repress their own transcription, forming the core feedback loop of the circadian clock .

Acetylation of BMAL1 at lysine 538 (K538) by the lysine acetyltransferase TIP60 is a critical regulatory mechanism in the circadian cycle. During the activating phase, this acetylation leads to the recruitment of BRD4 and the pause release factor P-TEFb to E-box-containing circadian promoters, enabling productive elongation of circadian transcripts . This represents a crucial temporal checkpoint in the circadian clock cycle.

How does the Acetyl-ARNTL (K538) Antibody differ from general ARNTL/BMAL1 antibodies?

The Acetyl-ARNTL (K538) Antibody specifically detects endogenous levels of BMAL1/ARNTL protein only when acetylated at lysine 538 . Unlike general ARNTL/BMAL1 antibodies that detect the protein regardless of its modification state, this antibody provides precise information about the acetylation status at this particular residue. This specificity makes it invaluable for studying the temporal dynamics of BMAL1 acetylation in circadian rhythm regulation and its downstream effects on transcriptional control .

What are the typical applications for Acetyl-ARNTL (K538) Antibody?

The Acetyl-ARNTL (K538) Antibody is primarily used in Western blot (WB) and ELISA applications . Some sources also indicate its application in immunohistochemistry (IH) . The recommended dilution ranges are:

These applications enable researchers to detect and quantify acetylated BMAL1 in various experimental contexts, from cell lysates to tissue sections, providing insights into circadian regulation in different biological systems .

What are the optimal experimental conditions for Western blot detection of Acetyl-BMAL1 (K538)?

For optimal Western blot detection of Acetyl-BMAL1 (K538), researchers should:

• Use freshly prepared lysates from synchronized cells to capture the circadian variation in acetylation levels.

• Apply a dilution between 1:500 and 1:2000 of the Acetyl-ARNTL (K538) Antibody in blocking buffer .

• Include appropriate controls, such as lysates from BMAL1 K538R mutant cells (where the lysine is mutated to arginine), which would not show a signal with this antibody .

• Use 293 cells as a positive control, as they have been validated for Western blot analysis with this antibody, as shown in product images .

• Store the antibody at -20°C for long-term storage, or at 2-8°C for up to two weeks to maintain reactivity .

These methodological considerations help ensure reliable and reproducible detection of acetylated BMAL1 in experimental samples.

How can researchers validate the specificity of Acetyl-ARNTL (K538) Antibody in their experimental systems?

To validate antibody specificity, researchers should implement several approaches:

These validation strategies ensure that observed signals genuinely represent acetylated BMAL1 at K538 rather than non-specific binding.

How does BMAL1 K538 acetylation affect downstream transcriptional elongation in the circadian cycle?

BMAL1 K538 acetylation serves as a critical regulatory mechanism for circadian transcription by:

• Providing a binding site for the bromodomain protein BRD4, which recognizes acetylated lysines on transcription factors and histones .

• Facilitating the recruitment of the pause release factor P-TEFb to E-box-containing circadian promoters.

• Enabling the release of RNA Polymerase II from its paused state at circadian gene promoters, allowing productive elongation of circadian transcripts.

Research comparing wild-type and BMAL1 K538R mutant cells revealed that mutation of this acetylation site led to:

• Markedly reduced enrichment of Ser2-phosphorylated RNA Polymerase II at circadian gene promoters

• Virtually no rhythmic luciferase reporter expression

• Pronounced reduction in peak expression of endogenous circadian genes (Dbp, Per1, and Nr1d1)

Importantly, the occupancy of the general transcription factor TFIIEα at the transcription start sites of these genes was not affected in mutant cells, indicating that acetylation primarily regulates transcription elongation rather than initiation .

What is the relationship between BMAL1 acetylation and metabolic regulation, particularly in adipocytes?

The relationship between BMAL1 acetylation and metabolic regulation involves several key aspects:

• Adipocyte-specific deletion of ARNTL/BMAL1 leads to obesity in mice, demonstrating its importance in adipose tissue function .

• Mice with adipocyte-specific ARNTL deletion develop adipocyte hypertrophy, with adipocytes approximately 30% larger than those from control mice .

• ARNTL2, a paralogue of ARNTL1, shows different expression patterns during adipogenic differentiation and weight loss. While ARNTL2 mRNA is downregulated in adipose stem/progenitor cells upon weight loss, ARNTL2 protein is rapidly induced during adipogenic differentiation .

• The acetylation state of BMAL1 at K538 likely affects its capacity to regulate adipocyte differentiation and function, though this relationship requires further investigation using tools like the Acetyl-ARNTL (K538) Antibody.

• Western blot analysis of subcutaneous white adipose tissue samples from normal-weight, obese, and weight-loss donors revealed unique expression patterns of ARNTL proteins, suggesting specialized functions in metabolic regulation .

These findings highlight the importance of studying BMAL1 acetylation in the context of metabolic disorders and potential therapeutic interventions.

What are common technical issues when using Acetyl-ARNTL (K538) Antibody and how can they be resolved?

Common technical issues and their solutions include:

For optimal storage, maintain the antibody in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide at -20°C for long-term storage or at 2-8°C for up to two weeks to avoid repeated freeze-thaw cycles that can diminish reactivity .

How should researchers interpret differences in Acetyl-BMAL1 (K538) levels across different experimental conditions?

When interpreting differences in Acetyl-BMAL1 (K538) levels, researchers should consider several factors:

• Circadian timing: Acetylation of BMAL1 at K538 fluctuates in a circadian manner. Differences may reflect sampling at different circadian phases rather than treatment effects. Include time-matched controls and consider time-course experiments .

• Total BMAL1 levels: Always normalize acetylated BMAL1 signal to total BMAL1 levels using a general BMAL1 antibody in parallel samples to distinguish between changes in acetylation and changes in total protein expression.

• TIP60 activity: As TIP60 is the acetyltransferase responsible for K538 acetylation, consider measuring TIP60 expression or activity in parallel to understand the mechanism behind observed differences .

• Cellular metabolic state: Since BMAL1 is involved in metabolic regulation, particularly in adipocytes, changes in cellular metabolism may affect acetylation levels. Consider measuring metabolic parameters alongside acetylation levels .

• Experimental manipulations: When using genetic approaches (e.g., CRISPR/Cas9 mutagenesis of K538), verify that the mutation doesn't affect other properties of BMAL1, such as stability, subcellular localization, or DNA binding capacity .

By taking these factors into account, researchers can make more accurate interpretations of changes in BMAL1 K538 acetylation levels and their biological significance.

How does the interplay between BMAL1 acetylation and other circadian clock components affect transcriptional regulation?

The interplay between BMAL1 acetylation and other circadian clock components creates a complex regulatory network:

• Acetylation of BMAL1 at K538 by TIP60 occurs during the activating phase of the circadian cycle and leads to recruitment of BRD4 and P-TEFb to circadian promoters .

• This recruitment facilitates the release of RNA Polymerase II from its paused state, enabling productive elongation of circadian transcripts for genes like Per1, Per2, Per3, Cry1, Cry2, Nr1d1, and Dbp .

• The products of these genes, particularly PER and CRY proteins, heterodimerize and repress their own transcription by interacting with the CLOCK/BMAL1 complex in a feedback loop .

• In BMAL1 K538R mutant cells, where acetylation cannot occur, there is significantly reduced expression of clock-controlled genes, despite normal binding of BMAL1 to circadian promoters. This indicates that acetylation affects post-binding transcriptional events rather than DNA binding itself .

• The repressor NR1D1 (REV-ERBα) is affected by BMAL1 acetylation, and its reduced expression in BMAL1-deficient adipocytes leads to increased expression of NPAS2 and CRY1, demonstrating the complex compensatory mechanisms within the circadian network .

This interplay creates precise temporal regulation of circadian gene expression, which is essential for proper physiological timing throughout the body.

What are the implications of disrupted BMAL1 acetylation for metabolic disorders and potential therapeutic interventions?

Disruption of BMAL1 acetylation has significant implications for metabolic disorders:

• Adipocyte-specific deletion of ARNTL/BMAL1 leads to obesity in mice with increased adipocyte size, suggesting a role for BMAL1 in limiting adipocyte hypertrophy .

• BMAL1 K538R mutation, which prevents acetylation, disrupts circadian rhythms and affects the expression of clock-controlled genes involved in metabolism .

• Misalignment of physiological circadian rhythms promotes obesity characterized by white adipose tissue expansion, linking circadian disruption to metabolic disorders .

• ARNTL2, a paralogue of ARNTL1/BMAL1, is regulated by weight loss and functions as an inhibitor of adipogenesis, potentially providing therapeutic opportunities for obesity .

Potential therapeutic approaches targeting BMAL1 acetylation include:

• Small molecule modulators of TIP60 acetyltransferase activity to enhance BMAL1 acetylation and potentially restore proper circadian gene expression in metabolic disorders.

• BRD4 inhibitors (like JQ1) that affect circadian rhythm could be repurposed or modified to specifically target circadian dysfunction in metabolic diseases .

• Chronotherapeutic approaches that align drug administration with optimal times for BMAL1 acetylation to enhance efficacy of metabolic interventions.

• Targeting the MAPK and mTOR signaling pathways that cooperatively maintain ARNTL2 protein in adipose stem/progenitor cells to potentially modulate adipocyte differentiation and function .